DLBS started to expand their wings to take its products into European and wider Asian markets. In collaboration with Phytonet AG, an independent consulting firm, to help push DLBS products on a global scale. This step begins with DLBS anti-diabetic product, Inlacin. Inlacin clinical trials have shown its efficacy for Diabetes mellitus Type-2. The product is currently marketed in Indonesia, , showing effectiveness in regulating blood sugar levels by prompting increased glucose uptake and decreasing the level of insulin resistance before and after the patient suffering diabetes. In addition, the lack of side-effects that may be occurred was also a key selling point. Dr. Cem Aydogan, CEO for Phytonet AG, told FoodNavigator-Asia that as a doctor, he is very enthusiastic about this product, since the scientific back-up is great.

For full information please follow this link:

http://www.foodnavigator-asia.com/Business/Indonesian-herbal-diabetic-drug-to-target-EU-and-Asia ).